First-in-Human Phase I Clinical Trial of SLC-391, a Novel and Selective AXL Inhibitor, in Patients with Advanced Solid Tumours

Zaihui Zhang, Donna Morrison, Liang Lu, Madhu Singh, Jun Yan, Natasha Leighl, Scott A Laurie, Sebastien Hotte, Serge Mordon · 2025

Read First-in-Human Phase I Clinical Trial of SLC-391, a Novel and Selective AXL Inhibitor, in Patients with Advanced Solid Tumours by Zaihui Zhang, Donna Morrison, Liang Lu, Madhu Singh, Jun Yan, Natasha Leighl, Scott A Laurie, Sebastien Hotte, Serge Mordon (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12736120.txt.

Description

Zaihui Zhang and co-authors run the first human trial of an AXL-blocking cancer drug, SLC-391, in a 2025 study. The AXL receptor helps tumors grow, spread, dodge immunity, and resist therapy, making it an inviting target. The oral drug had already shown punch in lab models.

Thirty-five patients with advanced solid tumors took rising daily or twice-daily doses in three-week cycles. The drug was generally well tolerated, and no maximum tolerated dose was reached. A few severe side effects clustered at the highest doses. Blood levels rose with dose and steadied by the third week. Twelve patients held stable disease, some for nearly a year. A mid-range twice-daily dose looked cleanest for further trials.

Catalog record

CREATORZaihui Zhang, Donna Morrison, Liang Lu, Madhu Singh, Jun Yan, Natasha Leighl, Scott A Laurie, Sebastien Hotte, Serge Mordon
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE53 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12736120

Browse the full library · About the Tower of Babel